Q-omics provides the consensus-scored PEDS1-UBE2V1 profile across patient tissues and cancer cell-line models. PEDS1-UBE2V1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PEDS1-UBE2V1 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, PEDS1-UBE2V1 protein abundance shows 23,688 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight SKCM, HNSC, and BRCA as cancer lineages where PEDS1-UBE2V1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEDS1-UBE2V1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEDS1-UBE2V1 survival associations across molecular data types. PEDS1-UBE2V1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEDS1-UBE2V1 RNA expression–survival associations across cancer types. High PEDS1-UBE2V1 expression shows unfavorable associations in OV, LIHC and ACC, but favorable associations in SKCM, THCA and SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PEDS1-UBE2V1 RNA expression.
This table summarizes PEDS1-UBE2V1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PEDS1-UBE2V1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEDS1-UBE2V1 shows higher tumor expression in HNSC, LUSC, STAD, KIRP and LIHC. The HNSC box plot shows higher PEDS1-UBE2V1 RNA expression in tumor versus normal tissue (log2 FC = +0.074, t-test p < 0.001).
This table shows molecular features associated with PEDS1-UBE2V1 in patient tissues and cancer cell lines. In patient samples, PEDS1-UBE2V1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PEDS1-UBE2V1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
